Ascelia Pharma AB news
Ascelia Pharma today announced and welcomed the results of independent market research showing that 84% of healthcare professionals will likely use Orviglance for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced kidney function.
The independently conducted survey asked 270 healthcare professionals in the US (radiologists, oncologists and nephrologists) about their choices of imaging and contrast agents in patients with cancer. The primary driver of the
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the last patient visit has been completed in the clinical study to evaluate the effect of liver impairment on the safety, pharmacokinetics and pharmacodynamics of the company’s lead drug candidate Orviglance. Preliminary results show that Orviglance was well tolerated in patients with liver impairment. The study is part of the ongoing pivotal clinical program for Orviglance and will be included in the marketing authoriza
Ascelia Pharma AB (publ) (ticker: ACE) today announced that due to the Russian invasion of Ukraine, all clinical activities in Russia in the ongoing Phase 3 study SPARKLE are being suspended. As a consequence, the expected recruitment completion for the SPARKLE study is extended to 2022 (previously H1 2022).
The consequences of Russia’s invasion of Ukraine are both grave and concerning. Because of the escalating situation, Ascelia Pharma ha
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the study where Orviglance was compared against a gadolinium-based contrast agent has been accepted as an oral scientific presentation at the ESGAR conference to be held in May 31 – June 3 in Lisbon, Portugal.
“We are very pleased that the study has been selected as an oral scientific presentation at the prestigious European Society of Gastrointestinal and Abdominal Radiology
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for the upcoming global Phase 2 clinical study in gastric cancer with the daily oral chemotherapy candidate drug Oncoral.
“We are very happy that the FDA has accepted our IND application to start our Phase 2 study with Oncoral in the US, which is an important step